Rasdegafusp alfa

Drug Overview

Rasdegafusp alfa (formerly known as CAN04) is a pioneering “Smart Drug” designed to treat aggressive solid tumors. It is a highly specialized Immunotherapy and Targeted Therapy. Instead of broadly attacking all cells like traditional chemotherapy, this drug acts as a precise biological key that identifies and blocks the specific proteins cancer cells use to hide and grow.

Developed with a focus on precision medicine, rasdegafusp alfa targets the root cause of inflammation within the tumor environment. By shutting down these inflammatory signals, the drug makes the tumor more “visible” to the patient’s natural immune system. It represents a significant advancement for patients with difficult-to-treat cancers, such as those of the lung and pancreas.

• Generic Name: Rasdegafusp alfa
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Interleukin-1 Receptor Accessory Protein (IL1RAP) Targeting Monoclonal Antibody
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational (Currently in Phase II/III Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how rasdegafusp alfa works, imagine a tumor is a fortress protected by a thick fog (inflammation). This fog prevents the body’s natural defense force (immune cells) from seeing or attacking the fortress. Rasdegafusp alfa acts as a “fog-clearing” device.

At the molecular level, rasdegafusp alfa works through a multi-step targeted process:

1. Binding to IL1RAP: The drug is a humanized monoclonal antibody that specifically targets a protein called IL1RAP (Interleukin-1 Receptor Accessory Protein). This protein is found in high amounts on the surface of many cancer cells but is rare on healthy cells.
2. Blocking Inflammation: IL1RAP is essential for the signaling of Interleukin-1 (IL-1). IL-1 is a chemical messenger that tumors use to create a “pro-tumor” environment. By blocking IL1RAP, rasdegafusp alfa stops IL-1 from sending its growth signals.
3. Inhibiting the Signaling Pathway: When the drug binds to the receptor, it shuts down the NF-κB and MAPK signaling pathways. These are the internal communication lines that tell a cancer cell to multiply and resist treatment.
4. ADCC (Immune Attack): Beyond just blocking signals, the drug “flags” the cancer cell. This triggers Antibody-Dependent Cellular Cytotoxicity (ADCC), where the body’s natural “Natural Killer” (NK) cells recognize the flag and directly destroy the cancer cell.

FDA-Approved Clinical Indications

As an investigational agent, rasdegafusp alfa is currently available only through registered clinical trials.

Oncological Uses (Investigational)

• Non-Small Cell Lung Cancer (NSCLC): Being studied in combination with chemotherapy for patients whose cancer has spread.
• Pancreatic Adenocarcinoma: Investigated as a first-line treatment alongside standard chemotherapy regimens.
• Triple-Negative Breast Cancer: Early research into tumors that do not respond to hormone therapies.

Non-Oncological Uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Rasdegafusp alfa is administered by specialized healthcare teams in a clinical or hospital setting.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Because this is a protein-based antibody, it is not processed by the liver or kidneys like chemical drugs. However, doctors monitor organ function closely to ensure overall patient safety.

Clinical Efficacy and Research Results

Clinical data from studies conducted between 2020 and 2026 (such as the CANFOUR trials) show promising evidence of the drug’s “synergy” with chemotherapy.

• Tumor Shrinkage: In Phase II trials for pancreatic cancer, numerical data showed that combining rasdegafusp alfa with chemotherapy led to a Shrinkage Rate (ORR) that was significantly higher than chemotherapy alone.
• Progression-Free Survival (PFS): Early results suggest that patients receiving this targeted therapy lived longer without their disease getting worse compared to historical averages for aggressive lung and pancreatic cancers.
• Biomarker Response: Research confirmed a significant reduction in C-reactive protein (CRP) levels in patients, proving the drug successfully reduced tumor-related inflammation.

Safety Profile and Side Effects

Black Box Warning:

None. (Investigational drugs do not yet have formal Black Box Warnings, but they are monitored under strict safety protocols).

Common Side Effects (>10%)

• Infusion-Related Reactions: Chills, fever, or flushing during the IV drip.
• Fatigue: Feeling unusually tired or weak.
• Nausea: General stomach upset.
• Neutropenia: A temporary drop in white blood cell counts (mostly when used with chemotherapy).

Serious Adverse Events

• Severe Allergic Reactions: Rare instances of difficulty breathing or low blood pressure.
• Cytokine Release: A temporary over-activation of the immune system.

Management Strategies

• Pre-medication: Patients are often given an antihistamine and a fever reducer before the infusion to prevent reactions.
• Slowing the Drip: If a reaction occurs, the nurse can slow down the infusion to help the body adjust.

Research Areas

In the fields of Immunotherapy and Regenerative Medicine, rasdegafusp alfa is being studied for its ability to “re-program” the area around a tumor. Scientists are investigating how blocking IL1RAP can help the body’s Stem Cells recover from the damage caused by chemotherapy. Current research (2025-2026) is also looking at using this drug in combination with Checkpoint Inhibitors to see if it can help the immune system regenerate its natural cancer-fighting abilities more effectively.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• IL1RAP Expression Test: To confirm if the tumor has the specific protein target.
• Baseline Blood Counts (CBC): To establish starting immune cell levels.
• Liver and Kidney Function Panels.

Precautions During Treatment

• Infusion Day: Plan to spend several hours at the clinic for monitoring.
• Infection Watch: Because your white blood cell count may drop, avoid large crowds or people who are sick.

“Do’s and Don’ts” List

• Do stay hydrated before and after your infusion.
• Do report any “shaking chills” or rashes to your nurse immediately.
• Don’t skip your follow-up blood tests; they are vital for checking your safety.
• Don’t assume a mild fever is normal; always call your care team to be sure.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Rasdegafusp alfa is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This content reflects data available as of 2026.